Adding Cardiovascular Biomarkers to Established Risk Factors Increases Risk Prediction
By Elana Gotkine HealthDay Reporter
MONDAY, May 13, 2024 -- The addition of cardiovascular biomarkers to established risk factors leads to a small improvement in risk prediction of cardiovascular disease, according to a study published online May 13 in the Journal of the American Medical Association.
Johannes Tobias Neumann, M.D., Ph.D., from University Medical Center Hamburg-Eppendorf in Germany, and colleagues examined the prognostic value of routinely available cardiovascular biomarkers when added to established risk factors using data from 28 general population-based cohorts from 12 countries. The analyses included 164,054 individuals, with a median follow-up of 11.8 years.
The researchers identified 17,211 incident atherosclerotic cardiovascular disease events. Significant associations were seen for all biomarkers with incident atherosclerotic disease (subdistribution hazard ratio per 1-standard deviation change, 1.13, 1.18, 1.21, 1.14, and 1.14 for high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, B-type natriuretic peptide, and high-sensitivity C-reactive protein, respectively) and for all secondary outcomes. The C-statistic was improved with the addition of each single biomarker to a model that included established risk factors. In people younger than 65 years, the C-statistic for 10-year incident atherosclerotic cardiovascular disease improved from 0.812 to 0.8194 with the combination of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein. The most pronounced improvements in risk prediction were seen for the secondary outcomes of heart failure and all-cause mortality.
"The addition of biomarkers to established risk factors led to only a small improvement in risk prediction metrics for atherosclerotic cardiovascular disease, but was more favorable for heart failure and mortality," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.